
Qiming Venture Partners USA
Palo Alto, California, United StatesFounded 2017
Qiming Venture Partners USA is an entity of Qiming Venture Partners, a firm primarily focused on early-stage and growth-stage investments in the TMT (Technology, Media, Telecom) and Healthcare sectors in China.
62% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (46% of deals). Average disclosed round size is $67.3M (across 13 rounds with reported amounts).
Portfolio
13
Fund Size
$550M
Top Stage
Series A
Last 12 Mo
3
Team
AF
Anna French
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
13 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series B | $85M | Jan 2026 | |
| Series A | $65M | Sep 2025 | |
| Series A | $15M | May 2025 | |
| Series C | $100M | Jan 2025 | |
| SSoda Health | Series B | $50M | Dec 2024 |
| Series A | $70M | Jul 2023 | |
| SSoda Health | Series A | $25M | Sep 2022 |
| Series A | $48M | Jul 2022 | |
| Series B | $210M | Jun 2021 | |
| Series B | $53.5M | Jan 2021 | |
| Series A | $53M | Nov 2020 | |
| Series C | $71M | May 2020 | |
| Series B | $30M | May 2019 |
Top Co-Investors
DCVC4 shared
MPM Capital3 shared
Alexandria Venture Investments3 shared
Lightspeed Venture Partners2 shared
Cormorant Asset Management2 shared
SoftBank Vision Fund2 shared
CaaS Capital2 shared
Eli Lilly and Company2 shared
Sofinnova Partners2 shared
F-Prime Capital2 shared
Eight Roads Ventures2 shared
Casdin Capital2 shared
General Catalyst1 shared
Silicon Valley Bank1 shared
Illumina Ventures1 shared
HLM Venture Partners1 shared
Deerfield1 shared
Transformation Capital1 shared
Optum Ventures1 shared
RA Capital Management1 shared
Last updated: 15 April 2026